Pre-retrieval reperfusion decreases cancer recurrence after rat ischemic liver graft transplantation  by Cheng, JiWen & Lv, Yi
Pre-retrieval reperfusion decreases cancer recurrence
after rat ischemic liver graft transplantation
JiWen Cheng
Yi Lv⇑
Department of Hepatobiliary Surgery, The First Afﬁliated Hospital of
Medical College, Xi’an Jiaotong University, Xi’an, Shaanxi Province,
China
Institute of Advanced Surgical Technology and Engineering, Xi’an
Jiaotong University, Xi’an, Shaanxi Province, China⇑Corresponding author.
E-mail address: luyi169@126.com
Letters to the EditorTo the Editor:
We read with great interest the article ‘‘Pre-retrieval reperfusion
decreases cancer recurrence after rat ischemic liver graft
transplantation’’ [1]. This elegant study assessed the impact of
ischemic liver graft on the risk of cancer recurrence utilizing a
rat liver transplantation model. Oldani et al. [1] demonstrated
that ischemia/reperfusion lesions lead to an increased risk of
post-transplant hepatocellular carcinoma (HCC) recurrence and
growth, which can be reversed by graft reperfusion prior to
retrieval. However, in this study, they clamped the vena porta
and infra-hepatic vena cava during 10 or 30 min prior to ﬂushing
and retrieving the liver to simulate the ischemic donors, and the
liver was reperfused for two hours after all clamps were removed
at the end of the clamping to simulate ischemic/reperfused
donors. Apparently, the quality of blood reperfused in this
transplantation model is better than the perfusion solution used
during normothermic extracorporeal membrane oxygenation
(NECMO) after circulatory death in clinical situations to some
extent [2]. Thus, we wonder if the risks of post-transplant cancer
recurrence can be reduced by graft reperfusion with ‘‘perfusion
solution’’ used in clinical prior to retrieval?
In addition in a further study, it is necessary to estimate the
combined feasibility and availability of pre-retrieval reperfusion
with different NECMO time with the aim to reduce the risk of
cancer recurrence and to repair and resuscitate the liver grafts
from donation after cardiac death (DCD) donors. This may helpReply to: ‘‘Pre-retrieval reperfusion
rat ischemic liver gra
To the Editor:
We thank Drs Cheng and Lv [1] for their interest in our work sug-
gesting an increased rate of hepatocellular carcinoma (HCC)
recurrence/growth after transplantation of ischemic liver grafts,
and the protective effect of in situ graft reperfusion prior to
retrieval [2].
Our rat transplantation model only approximates clinical real-
ity. It used liver grafts undergoing 10 or 30 min of ischemia prior
to retrieval (clamping the porta hepatis and the infra-hepatic
vena cava in the donor). HCC cells were injected intra-portally,
and liver HCC volumes were repeatedly assessed by magnetic
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Open access under CC BY-NC-ND license.to increase the yield of transplantable livers from this source
for HCC candidates awaiting liver transplantation.
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resonance imaging. A two-hour donor liver reperfusion prior to
retrieval was reversing the effects of ischemia/reperfusion and
was associated to lower rates of post-transplant HCC growth.
Normothermic extracorporeal membrane oxygenation (NEC-
MO) is the closest clinical procedure to reproduce the studied
model, as it allows restoring the perfusion of the donor organs
in case of donation after cardiac death (DCD). Apart from being
primed with a perfusion solution, NECMO uses the donor’s own
blood, with a maintained pH between 7.0 and 7.4 [3]. However,
it is currently unknown whether NECMO can also have a protec-
tive impact on post-transplant HCC recurrence/growth, and this
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